Virosome studied by MedImmune

By Dylan Bushell-Embling
Friday, 18 July, 2008

Technology developed by Norwood Abbey's [ASX: NAL] second-tier subsidiary Virosome Biologicals is being evaluated by US company MedImmune.

The companies have signed a six-month exclusive evaluation agreement over Virosome's virosomal vaccine technology. In this time the companies will collaborate on research using the virosome technology with MedImmune vaccine candidates.

MedImmune is a member of the AstraZeneca group.

Proposed Australian trial eyes up blood testing for Alzheimer's

Utilising networks of GPs across three states, a large-scale study intends on combining digital...

Applications open for $300K pandemic therapeutics fellowships

Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...

CTA granted for CAR-T cell therapy for multiple myeloma

The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...

Content from other channels on our network

What can food manufacturers learn from viral food trends?

Lion 'flicks the switch' to electric at Speight's Brewery

NZ Winegrowers calls for a White Wine Emoji

Nutrition claims compliance, fresh produce guide updated

Automation and process control for new beverage canning facility

Leafy greens identified as potential metal mining tools

Smart monitoring helps tram network cut water use by 70%

NSW closes EV gaps in regional areas

Call for 10c increase on container return schemes

Water transition key at Global Water Summit 2026

National Pain Alliance launched to advocate for chronic pain

Sexual misconduct findings added to public register under "landmark reforms"

Australia invests further $14.6 million in national allergy research

Can seasonal influenza vaccination prime the immune system for future strains?

"Targeted supports" launched for former patients of Simon Gordon